Across the recent three months, 4 analysts have shared their insights on Tandem Diabetes Care TNDM, expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.5, a high estimate of $38.00, and a low estimate of $24.00. This current average reflects an increase of 34.02% from the previous average price target of $24.25.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Tandem Diabetes Care by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joanne Wuensch | Citigroup | Raises | Neutral | $38.00 | $31.00 |
| Mathew Blackman | Stifel | Raises | Buy | $37.00 | $24.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $31.00 | $25.00 |
| Rick Wise | Stifel | Raises | Hold | $24.00 | $17.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Tandem Diabetes Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Tandem Diabetes Care's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Tandem Diabetes Care analyst ratings.
Delving into Tandem Diabetes Care's Background
Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Breaking Down Tandem Diabetes Care's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Tandem Diabetes Care faced challenges, resulting in a decline of approximately -10.75% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tandem Diabetes Care's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -15.25%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tandem Diabetes Care's ROE excels beyond industry benchmarks, reaching -9.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tandem Diabetes Care's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio surpasses industry norms, standing at 1.33. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
